ANSWER: C

Rationale:

All Class I antiarrhythmic agents act through blockade of Nav1.5, the voltage-gated cardiac fast sodium channel encoded by the SCN5A gene. Nav1.5 is the dominant sodium channel isoform in ventricular myocardium and the His-Purkinje system, and its opening during phase 0 of the cardiac action potential generates the rapid inward sodium current (INa) responsible for the fast upstroke velocity (dV/dtmax) that determines conduction velocity. Class I agents bind preferentially to Nav1.5 channels in their open or inactivated states, reducing the amplitude and velocity of phase 0 depolarization. This reduction in conduction velocity is the pharmacodynamic basis for their antiarrhythmic action: slowing conduction in re-entrant circuits can convert unidirectional block to bidirectional block, terminating the arrhythmia. The degree and kinetics of this blockade differ across the three subclasses (Ia, Ib, Ic), but the molecular target is the same.

• Option A: Option A is incorrect: L-type calcium channels (Cav1.2) are the target of Class IV agents (verapamil, diltiazem), not Class I agents; calcium channels govern the phase 0 upstroke in nodal tissue and the plateau phase in ventricular myocardium, but fast sodium channels drive ventricular conduction.
• Option B: Option B is incorrect: IKr potassium channels encoded by KCNH2 are not the primary target of Class I agents; IKr blockade is the mechanism of Class III agents (and a secondary effect of Class Ia agents) that prolongs repolarization and the QT interval; it is not what defines Class I action.
• Option D: Option D is incorrect: IKs (slow delayed rectifier) is also a repolarizing potassium current and not the target of Class I agents; its blockade by Class Ia agents is incidental to their primary sodium channel effect.
• Option E: Option E is incorrect: HCN4 and the pacemaker current If are the targets of ivabradine (an unclassified agent); Class I agents do not act primarily on sinoatrial automaticity through If blockade.

ANSWER: A

Rationale:

Use-dependence (frequency-dependence) is the defining pharmacodynamic property of all Class I antiarrhythmic agents and arises directly from their state-selective channel binding. Nav1.5 cycles through three functional states: resting (closed, drug-inaccessible), open (drug-accessible), and inactivated (drug-accessible). Class I agents bind with highest affinity to channels in the open and inactivated states. At faster heart rates, each channel cycles more frequently from resting through open to inactivated per unit time, meaning more channels are available for drug binding per minute. This increases the proportion of blocked channels and amplifies the reduction in phase 0 upstroke velocity and conduction velocity. The clinical consequence is that Class I agents produce progressively greater conduction slowing as heart rate increases, which is why QRS duration widens more at faster rates on flecainide, why these drugs are more effective at terminating tachyarrhythmias than suppressing arrhythmias during bradycardia, and why they carry greater proarrhythmic risk during rapid ventricular tachycardia.

• Option B: Option B is incorrect: use-dependence does not require a prior channel opening event in the naive sense described; the agent simply preferentially accumulates block during the open and inactivated states that occur with each action potential cycle; the distinction from resting-state binding is quantitative affinity, not an absolute prerequisite.
• Option C: Option C is incorrect: sodium channel upregulation with repeated drug dosing is not use-dependence; use-dependence is an acute, cycle-to-cycle pharmacodynamic phenomenon, not a chronic tolerance mechanism.
• Option D: Option D is incorrect: this option inverts the correct relationship between dissociation kinetics and use-dependence; Class Ic agents with slow dissociation accumulate more block at physiological rates, not less; fast dissociation (Class Ib) actually allows block to recover fully between beats at normal rates, reducing accumulation.
• Option E: Option E is incorrect: while it is true that depolarized or ischemic tissue provides more drug-accessible inactivated channels, use-dependence as a term specifically refers to the rate-dependent accumulation of block, not preferential binding to ischemic tissue; that tissue selectivity is a separate concept.

ANSWER: E

Rationale:

Class Ia agents occupy the intermediate kinetic position in the Harrison subclassification, with sodium channel recovery times of approximately 1 to 10 seconds. This intermediate recovery means that at physiological heart rates, a significant proportion of channels remain blocked at the end of each diastolic interval, producing measurable but moderate QRS widening. The defining additional feature of Class Ia agents ; which distinguishes them from Class Ib and Ic agents ; is concurrent blockade of IKr potassium channels (the rapid delayed rectifier). IKr blockade prolongs the action potential duration and the QT interval, which is reflected as a prolonged QTc on the surface ECG. This dual effect (sodium channel block slowing conduction + IKr block prolonging repolarization) creates a characteristic ECG signature: both QRS widening and QTc prolongation. The primary proarrhythmic risk from this combination is torsades de pointes (TdP), which arises from the excessive QT prolongation through early afterdepolarization formation. The three Class Ia agents ; quinidine, procainamide, and disopyramide ; differ in their secondary pharmacological properties (quinidine has antimuscarinic and alpha-blocking effects; procainamide is metabolized to NAPA; disopyramide has the most pronounced negative inotropy) but share this kinetic and ECG profile.

• Option A: Option A is incorrect: this description defines Class Ib agents (fast kinetics, APD shortening, lidocaine/mexiletine), not Class Ia.
• Option B: Option B is incorrect: this description defines Class Ic agents (slow kinetics, marked QRS widening without QT change, flecainide/propafenone, CAST contraindication), not Class Ia.
• Option C: Option C is incorrect: Class Ia agents do not activate IKr; they block it, producing QT prolongation, not QT shortening; their proarrhythmic risk is TdP, not AV block.
• Option D: Option D is incorrect: preferential binding to ischemic myocardium through the inactivated state is a property shared by Class Ib agents (particularly lidocaine) rather than a distinguishing feature of Class Ia agents; fast kinetics are Class Ib, not Class Ia.

ANSWER: B

Rationale:

Class Ib agents are characterized by fast recovery kinetics ; their time constant for dissociation from blocked sodium channels is less than 1 second. This rapid unbinding has a profound clinical consequence: at physiological heart rates of 60 to 100 beats per minute, the diastolic interval (approximately 600 to 800 ms) is long enough for essentially complete channel recovery before the next action potential. This means that at normal rates, Class Ib agents produce minimal net accumulation of channel block, minimal conduction slowing, and minimal QRS widening. Their use-dependence is therefore clinically apparent primarily during tachyarrhythmias, when shortened diastolic intervals prevent full recovery and block accumulates. Class Ib agents also have a distinct action on the action potential: they shorten action potential duration (APD), which distinguishes them from both Class Ia (which prolong APD through IKr block) and Class Ic (which have minimal effect on APD). The shortened APD reduces the window for early afterdepolarization formation, contributing to the low proarrhythmic risk of this subclass. Lidocaine is available only intravenously (poor oral bioavailability due to extensive first-pass hepatic metabolism); mexiletine is its oral equivalent.

• Option A: Option A is incorrect: slow recovery kinetics and marked QRS widening describe Class Ic agents, not Class Ib; the characterization of lidocaine as used exclusively for VF termination is also too narrow.
• Option C: Option C is incorrect: Class Ib agents have fast kinetics and shorten APD through sodium channel-dependent mechanisms, not through IKr activation; the kinetic description (intermediate) is wrong.
• Option D: Option D is incorrect: Class Ib agents actually preferentially bind to inactivated (depolarized) sodium channels ; which are more prevalent in ischemic tissue ; not healthy myocardium; this selective binding to ischemic tissue is a therapeutic advantage, not a danger.
• Option E: Option E is incorrect: lidocaine has poor oral bioavailability and is intravenous only; mexiletine does have reasonable oral bioavailability, but neither is used for AF rhythm control; Class Ib agents are not indicated for AF and are not appropriate substitutes for Class Ic agents in structural heart disease.

ANSWER: D

Rationale:

Class Ic agents have the slowest recovery kinetics of all Class I subgroups ; greater than 10 seconds ; meaning that once a sodium channel is blocked, it cannot fully unbind and recover during the normal diastolic interval at physiological heart rates (60 to 100 bpm). Block therefore accumulates with each successive action potential: after the first beat some channels are blocked; before they can recover, the next action potential arrives and adds more block. This progressive accumulation produces marked slowing of phase 0 upstroke velocity, significant widening of the QRS duration, and slowing of conduction velocity throughout the ventricles and His-Purkinje system. Crucially, this slowing is heterogeneous ; it varies across regions of different channel density, fibrosis, and ischemia ; and in structurally diseased myocardium creates new re-entrant circuits or converts functional block into anatomical re-entry, precipitating monomorphic VT or VF. Unlike Class Ia agents, Class Ic drugs produce minimal blockade of IKr potassium channels and therefore cause minimal QT prolongation; their primary ECG marker is QRS widening. Flecainide and propafenone are the two principal Class Ic agents in clinical use.

• Option A: Option A is incorrect: QT prolongation as the primary ECG effect and TdP as the primary proarrhythmia, together with the agent list (quinidine, procainamide, disopyramide), describes Class Ia, not Class Ic.
• Option B: Option B is incorrect: fast recovery kinetics describe Class Ib agents; Class Ic agents have the slowest kinetics; the suggestion that Class Ic agents are preferred in structural heart disease is the opposite of the clinical reality established by CAST.
• Option C: Option C is incorrect: intermediate kinetics describe Class Ia agents; flecainide is a Class Ic agent; combining lidocaine (Class Ib) and flecainide (Class Ic) in the same subclass is incorrect.
• Option E: Option E is incorrect: CAST demonstrated that Class Ic agents increase mortality in structural heart disease; the option inverts the trial's finding; there is no mortality benefit of Class Ic agents in post-MI patients.

ANSWER: C

Rationale:

Quinidine has clinically significant antimuscarinic (anticholinergic) properties that arise from its blockade of muscarinic M2 receptors on sinoatrial and atrioventricular nodal cells. Under normal conditions, vagal tone continuously activates M2 receptors to slow the sinus rate and limit AV nodal conduction velocity. When quinidine blocks M2 receptors, this vagal brake is removed: the sinus rate increases (sinus tachycardia) and AV nodal conduction velocity increases (shortened AV nodal refractory period). The sinus tachycardia is a commonly observed clinical finding in patients started on quinidine. The AV nodal effect carries critical clinical significance in atrial flutter: quinidine's Class Ia sodium channel blockade in atrial tissue slows the flutter rate from the typical 300 beats per minute toward 200 to 250 beats per minute, while simultaneously its antimuscarinic effect enhances AV nodal conduction. A flutter rate of 220 beats per minute may now conduct 1:1 through an AV node that has lost its physiological refractoriness from vagal tone, producing a ventricular rate of 220 beats per minute ; hemodynamically catastrophic and directly attributable to the drug. This outcome is precisely why quinidine (and other Class Ia agents) must always be co-prescribed with an AV nodal blocking agent when used in atrial flutter.

• Option A: Option A is incorrect: the antimuscarinic effects on GI and urinary smooth muscle are mediated by M3 receptors, not M2; while quinidine does have anticholinergic adverse effects (constipation, urinary retention), the cardiac M2 effect is more clinically significant in the arrhythmia context.
• Option B: Option B is incorrect: quinidine's antimuscarinic effect removes vagal inhibition from the sinus node, producing sinus tachycardia, not bradycardia; it does not act through beta-adrenergic receptor stimulation.
• Option D: Option D is incorrect: bronchial smooth muscle M3 blockade is not a clinically significant pharmacological feature of quinidine; its antimuscarinic profile primarily affects cardiac M2 receptors at the doses used for antiarrhythmic therapy.
• Option E: Option E is incorrect: quinidine does have alpha-adrenergic blocking properties that can cause peripheral vasodilation and reflex tachycardia, but these do not counteract the AV nodal M2 blocking effect; both effects coexist and the AV nodal enhancement from M2 block is the clinically dominant concern in flutter management.

ANSWER: A

Rationale:

Procainamide-induced drug-induced lupus-like syndrome (DILS) is one of the most commonly encountered drug-induced autoimmune syndromes in clinical practice. ANA positivity develops in 50 to 80 percent of patients on chronic procainamide therapy, though clinical symptoms (arthralgia, pleuritis, pericarditis, malar rash) develop in only 20 to 30 percent. The clinical syndrome closely resembles idiopathic systemic lupus erythematosus in its musculoskeletal and serositis manifestations, but is reliably distinguished from idiopathic SLE by the absence of anti-double-stranded DNA antibodies (which are the hallmark of idiopathic SLE) and by its reversibility after drug discontinuation. The pathogenesis involves reactive metabolites of procainamide ; particularly hydroxylamine intermediates formed through N-oxidation pathways ; that modify nuclear protein antigens and trigger an autoimmune response. Acetylator status substantially modulates risk: slow acetylators convert procainamide to NAPA (N-acetylprocainamide) more slowly, resulting in higher concentrations of the parent compound and its immunogenic hydroxylamine metabolites; they develop DILS significantly more frequently and more rapidly than fast acetylators, who rapidly convert to NAPA, which has lower immunogenic potential.

• Option B: Option B is incorrect: anti-dsDNA antibodies are characteristically absent in procainamide DILS ; their presence would point toward idiopathic SLE; fast acetylators are at lower risk, not higher risk, because they convert procainamide more quickly to the less immunogenic NAPA.
• Option C: Option C is incorrect: DILS is not characterized by nephritis or glomerular disease; the primary manifestations are articular and serositis; NAPA nephrotoxicity from accumulation in renal impairment is a pharmacokinetic concern but is not the mechanism of DILS.
• Option D: Option D is incorrect: DILS does not affect all patients uniformly within 12 months; its incidence and timing vary with acetylator status and dose; C1q activation is not the established mechanism; DILS is generally reversible after discontinuation, not requiring permanent immunosuppression.
• Option E: Option E is incorrect: DILS is not caused by antimuscarinic properties or B-cell polyclonal activation through acetylcholine receptor blockade; the mechanism is through reactive metabolite modification of nuclear proteins; resolution is gradual over weeks to months, not within 48 hours.

ANSWER: E

Rationale:

Among the three Class Ia antiarrhythmic agents, disopyramide stands out for its pronounced negative inotropic effect on ventricular myocardium, which is substantially greater than that of quinidine or procainamide. This property is attributed in part to calcium channel-blocking activity in addition to the shared sodium channel blockade of the Class Ia group. In patients with impaired ventricular function ; even mildly reduced ejection fraction ; disopyramide can precipitate acute decompensated heart failure by further impairing contractility. This makes it among the most hazardous antiarrhythmics to prescribe in HFrEF and potentially dangerous even in patients with borderline systolic function. However, this same negative inotropy becomes specifically therapeutic in obstructive hypertrophic cardiomyopathy (HOCM). In HOCM, the dynamic left ventricular outflow tract (LVOT) gradient is driven by hypercontractile myocardium and the Venturi-mediated systolic anterior motion of the mitral valve. By reducing ventricular contractility, disopyramide decreases the LVOT gradient and alleviates symptoms. Current hypertrophic cardiomyopathy guidelines recognize disopyramide as a reasonable pharmacological option for symptomatic LVOT obstruction, typically combined with an AV nodal blocking agent to counteract disopyramide's antimuscarinic AV nodal enhancement. This is a niche indication where the most limiting adverse effect in most contexts becomes the mechanism of therapeutic benefit.

• Option A: Option A is incorrect: disopyramide does not selectively block L-type calcium channels in the way verapamil does; its calcium channel-related effects are indirect contributions to negative inotropy, not a separate clinical calcium channel blockade; it does not provide AV nodal rate control independent of other agents.
• Option B: Option B is incorrect: disopyramide does not have pronounced alpha-adrenergic blocking properties; this effect is associated with quinidine, not disopyramide; disopyramide actually has anticholinergic properties that can raise blood pressure slightly through peripheral vascular effects.
• Option C: Option C is incorrect: disopyramide does not have a half-life of 72 to 96 hours; its half-life is approximately 6 to 8 hours; the NAPA accumulation concern applies to procainamide, not disopyramide.
• Option D: Option D is incorrect: disopyramide blocks IKr (not IKs), like the other Class Ia agents; the comparison between IKs and IKr blockade described here is pharmacologically inaccurate.

ANSWER: B

Rationale:

Lidocaine's clinical use is defined by its pharmacokinetics. It undergoes extensive hepatic first-pass metabolism when administered orally, resulting in bioavailability of only approximately 3 percent ; far too low for effective oral dosing. It must therefore be administered intravenously for antiarrhythmic use, typically as a loading bolus (1 to 1.5 mg/kg) followed by a continuous infusion (1 to 4 mg/min). Hepatic elimination is rapid, with a half-life of approximately 90 to 120 minutes, requiring continuous infusion to maintain therapeutic concentrations. The therapeutic range is approximately 1.5 to 5 mcg/mL. The toxicity profile follows a predictable concentration-dependent sequence: at plasma concentrations of 3 to 6 mcg/mL, CNS symptoms appear (circumoral numbness, tinnitus, lightheadedness, slurred speech); at 5 to 9 mcg/mL, seizures can occur; cardiac toxicity (QRS widening, conduction block, ventricular arrhythmias) requires substantially higher concentrations of approximately 8 to 12 mcg/mL or more ; roughly two to four times the concentration producing initial CNS symptoms. This concentration hierarchy means CNS symptoms serve as an early warning of toxicity, allowing dose adjustment before cardiac toxicity supervenes.

• Option A: Option A is incorrect: lidocaine has very poor oral bioavailability (approximately 3 percent) due to extensive first-pass metabolism, not 85 percent; oral lidocaine is not used clinically; mexiletine is the oral Class Ib equivalent.
• Option C: Option C is incorrect: while MEGX (monoethylglycinexylidide) is a real hepatic metabolite of lidocaine with pharmacological activity, it is not the primary antiarrhythmic species; lidocaine itself is the active drug and MEGX contributes to both efficacy and CNS toxicity at toxic concentrations; lidocaine is not a prodrug.
• Option D: Option D is incorrect: lidocaine is hepatically eliminated, not renally; dose adjustment for renal impairment is not routinely required for the parent compound; QT prolongation is not lidocaine's primary toxicity signature.
• Option E: Option E is incorrect: the statement that cardiac toxicity consistently precedes CNS toxicity is the reverse of the true sequence; CNS symptoms appear at considerably lower concentrations than cardiac toxicity, providing a clinically useful warning hierarchy. SECTION 2 — Clinical Application (Questions 10–16)

ANSWER: D

Rationale:

LQT3 is caused by gain-of-function mutations in SCN5A (the gene encoding Nav1.5) that impair sodium channel inactivation, generating a persistent late inward sodium current (INa,late) during the plateau phase of the action potential. Normal sodium channels inactivate rapidly after opening, but LQT3 mutant channels continue to conduct a small but sustained inward current throughout the plateau, extending action potential duration and prolonging the QT interval. Mexiletine, as a Class Ib sodium channel blocker with rapid kinetics and preferential binding to inactivated channels, specifically targets INa,late ; the abnormal sodium current arising from channels that fail to fully inactivate. By blocking INa,late, mexiletine reduces the pathological depolarizing drive during the plateau, shortens action potential duration, and produces measurable QTc reduction in LQT3 patients. Clinical studies have confirmed that mexiletine shortens the QTc in LQT3 patients and it is used as an adjunct to beta-blocker therapy in this subtype. Critically, this mechanism is specific to LQT3: LQT1 (KCNQ1 loss-of-function) and LQT2 (KCNH2 loss-of-function) involve deficient repolarizing potassium current rather than excess sodium current, and mexiletine's sodium channel blockade has no mechanistic rationale in these subtypes.

• Option A: Option A is incorrect: LQT1 involves loss-of-function in KCNQ1 (IKs), a potassium channel; mexiletine's sodium channel blockade does not compensate for reduced IKs and is not specifically therapeutic in LQT1.
• Option B: Option B is incorrect: mexiletine does not activate IKr; it is a sodium channel blocker; there is no mechanism by which it restores deficient IKr in LQT2.
• Option C: Option C is incorrect: Brugada syndrome involves loss-of-function in SCN5A reducing peak INa; adding a sodium channel blocker like mexiletine would worsen Brugada by further reducing peak INa ; sodium channel blockers (including ajmaline and procainamide) are used as provocative tests to unmask Brugada pattern, not as therapy.
• Option E: Option E is incorrect: CPVT involves ryanodine receptor (RYR2) gain-of-function producing excessive SR calcium release; mexiletine does not act on RYR2 or SR sodium channels; flecainide has been studied in CPVT through a ryanodine receptor-related mechanism, but not mexiletine through this pathway.

ANSWER: C

Rationale:

This clinical scenario is a direct demonstration of use-dependent sodium channel blockade ; one of the most important pharmacodynamic concepts for Class I agents. At the slower resting heart rate of 62 beats per minute, the diastolic interval is relatively long, allowing more time for flecainide-bound sodium channels to partially recover during each cycle. Net channel block is lower, and the QRS is only modestly widened (96 ms vs presumably approximately 88 ms at baseline without drug). At the faster exercise rate of 105 beats per minute, each diastolic interval is substantially shorter, allowing less time for channel recovery; more channels remain blocked at the onset of each action potential, reducing phase 0 upstroke velocity further and widening the QRS to 132 ms. The increase from 96 ms to 132 ms represents a 37.5 percent increase over the resting-drug QRS ; well above the 25 percent threshold above baseline that is widely used as a clinical warning sign of sodium channel toxicity requiring dose reduction or discontinuation. In this patient without structural heart disease, the risk from this degree of QRS widening is lower than in a post-MI patient, but the finding warrants careful reassessment. The rate-dependent nature of QRS widening on flecainide is why exercise stress testing can be a useful tool for evaluating Class Ic toxicity.

• Option A: Option A is incorrect: while catecholamines do interact with cardiac electrophysiology, the QRS widening on flecainide is primarily explained by the rate-dependent kinetics of sodium channel recovery, not by a catecholamine-sodium channel synergism.
• Option B: Option B is incorrect: flecainide does not cause coronary vasospasm and does not have clinically significant alpha-adrenergic blocking properties; this mechanism is fabricated.
• Option D: Option D is incorrect: flecainide does not have antimuscarinic properties; antimuscarinic AV nodal effects are a feature of quinidine, not flecainide; flecainide's QRS widening is a direct sodium channel effect in ventricular myocardium and His-Purkinje tissue.
• Option E: Option E is incorrect: QRS widening on flecainide is not fixed and is not a physiological phenomenon unrelated to the drug; it is a pharmacodynamic consequence of use-dependent sodium channel blockade that directly increases with heart rate; this rate-dependence is well established.

ANSWER: A

Rationale:

Propafenone is classified as Class Ic based on its dominant mechanism ; slow-recovery-kinetics sodium channel blockade producing marked QRS widening ; but it possesses two additional pharmacological actions that distinguish it from flecainide. First, propafenone has weak beta-adrenergic blocking activity, approximately one-fortieth the potency of propranolol. This beta-blocking effect produces clinically measurable sinus bradycardia, reduction in heart rate during exercise, and AV nodal slowing that is more pronounced than what is seen with flecainide. Second, propafenone has weak L-type calcium channel blocking properties. The clinical implications of the beta-blocking component are significant: propafenone should be used with caution in patients with significant sinus node dysfunction (risk of symptomatic bradycardia) and is relatively contraindicated in patients with reactive airway disease or asthma, because even weak beta-1/beta-2 blockade can trigger bronchospasm in susceptible individuals. This is in contrast to flecainide, which has no beta-blocking properties. Like flecainide, propafenone carries the CAST-based contraindication in structural heart disease (prior MI, HFrEF).

• Option B: Option B is incorrect: propafenone has beta-blocking properties, not beta-agonist properties; it slows, rather than increases, the sinus rate and AV nodal conduction.
• Option C: Option C is incorrect: propafenone does not have potent IKr-blocking properties and does not produce significant QT prolongation; its primary ECG effect is QRS widening from sodium channel blockade, consistent with its Class Ic classification; TdP is not its characteristic proarrhythmia.
• Option D: Option D is incorrect: propafenone has no aldosterone receptor-blocking activity; this mechanism describes spironolactone; propafenone's antihypertensive effect, if any, is modest and related to beta-blockade.
• Option E: Option E is incorrect: propafenone does not have antimuscarinic properties; anticholinergic effects (sinus tachycardia, urinary retention, dry mouth) are properties of quinidine and particularly disopyramide, not propafenone.

ANSWER: E

Rationale:

The CAST trial (1989) is the defining trial that established the Class Ic contraindication in structural heart disease. The hypothesis was rational: post-MI patients have frequent ventricular premature beats (VPBs), VPBs are associated with increased mortality in this population, and Class Ic agents effectively suppress VPBs. The trial enrolled post-MI patients with asymptomatic or mildly symptomatic VPBs, randomized them to flecainide, encainide, or placebo after confirming VPB suppression on each drug during an open-label run-in period, and planned to follow them for approximately one year. The trial was stopped early by the Data Safety Monitoring Board because both active drugs ; despite effectively suppressing VPBs ; significantly increased arrhythmic death and total mortality compared with placebo. The relative risk of arrhythmic death was approximately 2.5-fold higher with active treatment. This was the landmark demonstration that: (1) VPB suppression is an inadequate surrogate endpoint for survival; (2) Class Ic agents are proarrhythmic in the setting of ischemic structural heart disease, likely through their slow-recovery sodium channel blockade creating new re-entrant circuits in heterogeneous peri-infarct myocardium; and (3) the contraindication of these agents in structural heart disease is non-negotiable regardless of the arrhythmia being treated.

• Option A: Option A is incorrect: CAST enrolled patients with asymptomatic or mildly symptomatic VPBs, not sustained VT; both drugs increased mortality, not reduced it.
• Option B: Option B is incorrect: CAST enrolled post-MI patients with ventricular arrhythmias, not patients with AF; the flutter 1:1 concern is a clinical observation, not a CAST finding.
• Option C: Option C is incorrect: both flecainide and encainide increased mortality in CAST; neither was mortality-neutral; encainide was subsequently withdrawn from the market, but this was because of the trial results showing increased mortality, not because of differential effects.
• Option D: Option D is incorrect: CAST did not establish an LVEF threshold above which Class Ic agents are safe; the contraindication applies to all structural heart disease from prior MI regardless of ejection fraction.

ANSWER: B

Rationale:

Flecainide is appropriate only in patients with structurally normal hearts. The 44-year-old woman in option B meets this requirement: she has paroxysmal AF, no cardiac history, normal LVEF, no wall motion abnormalities, no LVH, and normal coronary anatomy ; a structurally normal heart. Flecainide effectively maintains sinus rhythm in AF and carries low proarrhythmic risk in this setting. The CAST contraindication is defined by the presence of structural heart disease that creates heterogeneous myocardial substrate ; particularly ischemic scar, cardiomyopathy, or significant LVH ; in which slow-recovery sodium channel blockade can generate new re-entrant circuits rather than suppress existing ones.

• Option A: Option A is incorrect: a prior MI three years ago with LVEF of 42% constitutes structural heart disease; the CAST contraindication applies regardless of current LVEF above or below 40%; the ischemic scar substrate is the contraindication, not the ejection fraction per se.
• Option C: Option C is incorrect: while CAST specifically enrolled post-MI patients, the pharmacological principle underlying the contraindication ; sodium channel block in structurally diseased myocardium creating new re-entrant circuits ; applies equally to non-ischemic cardiomyopathy; current guidelines extend the contraindication to HFrEF regardless of etiology.
• Option D: Option D is incorrect: significant concentric LVH (wall thickness 16 mm) with longstanding hypertension creates a structural substrate with altered electrophysiology that increases proarrhythmic risk with Class Ic agents; preserved LVEF does not eliminate this risk; moderate to severe LVH is generally considered a contraindication to flecainide.
• Option E: Option E is incorrect: a remote silent MI with a fixed perfusion defect on stress imaging confirms the presence of ischemic scar ; exactly the structural substrate that creates proarrhythmic risk with Class Ic agents; the remoteness or electrical silence of the territory does not eliminate the heterogeneous conduction properties of peri-infarct tissue.

ANSWER: D

Rationale:

This clinical scenario illustrates the most important and potentially lethal proarrhythmic pattern of Class Ic therapy in AF: the conversion of AF to atrial flutter with 1:1 AV conduction. Flecainide's use-dependent sodium channel blockade in atrial tissue reduces atrial conduction velocity and slows the chaotic re-entrant circuits of AF. As the drug takes effect, the multiple re-entrant circuits characteristic of AF can organize into a single, slower re-entrant circuit ; atrial flutter ; at a rate of 200 to 250 beats per minute. This is lower than the typical flutter rate of 300 beats per minute, because flecainide is slowing atrial conduction. The clinical problem arises at the AV node: without an AV nodal blocking agent, the AV node can conduct each flutter impulse 1:1 because the relatively slower flutter rate falls within the conduction capacity of the unprotected AV node. The resulting ventricular rate of 200 to 250 beats per minute is hemodynamically devastating. The QRS complexes are wide because flecainide's use-dependent block at the very rapid ventricular rate produces marked intraventricular conduction slowing. This outcome is entirely preventable: co-prescription of an AV nodal blocking agent (beta-blocker, diltiazem, verapamil, or digoxin) is mandatory when flecainide is prescribed for AF, specifically to block 1:1 flutter conduction if this conversion occurs. This is a guideline-recommended precaution, not an optional measure.

• Option A: Option A is incorrect: structurally normal myocardium does not generate VT from Class Ic sodium channel blockade in the same way as ischemic scar; the ECG shows visible flutter waves at 220 bpm with 1:1 AV conduction, which confirms the mechanism is supraventricular, not ventricular.
• Option B: Option B is incorrect: the ECG pattern with visible organized flutter waves at 220 bpm is inconsistent with AF with aberration; aberrant conduction in AF produces an irregular ventricular response, not the regular 1:1 pattern seen here.
• Option C: Option C is incorrect: flecainide does not inhibit the Na+/K+-ATPase; this mechanism describes digoxin; flecainide's mechanism is sodium channel blockade and does not affect the AV node through this pathway.
• Option E: Option E is incorrect: flecainide has no beta-agonist properties; it does not accelerate SA nodal automaticity; the rhythm shown is organized atrial flutter, not sinoatrial re-entrant tachycardia.

ANSWER: C

Rationale:

Quinidine's proarrhythmic profile differs fundamentally from that of Class Ic agents. While Class Ic proarrhythmia arises from sodium channel block creating re-entry in structurally diseased myocardium (monomorphic VT), quinidine's primary proarrhythmic risk is torsades de pointes (TdP), a polymorphic ventricular tachycardia with a characteristic twisting morphology. TdP arises from quinidine's concurrent blockade of IKr potassium channels (the rapid delayed rectifier), which prolongs action potential duration and the QT interval, creating conditions for early afterdepolarization (EAD) formation. The rate-dependence of this proarrhythmic effect is counterintuitive: IKr block produces greater QT prolongation at slow heart rates (reverse use-dependence), because the extended diastolic interval at slow rates allows greater drug-channel interaction time, more complete IKr block, and more pronounced APD extension. At faster heart rates, the diastolic interval is shorter, IKr block is less complete, and the QTc is correspondingly shorter. This means TdP risk with quinidine is paradoxically greatest during bradycardia, pauses, or at rest ; when heart rate is slowest ; rather than during tachycardia. This pattern of pause-triggered TdP causing sudden syncope was historically recognized as "quinidine syncope," reported as early as the 1920s before the electrophysiological mechanism was understood.

• Option A: Option A is incorrect: while quinidine has sodium channel-blocking properties, its primary proarrhythmic risk is TdP from IKr blockade, not monomorphic VT from re-entry in structural disease; quinidine is actually less likely than Class Ic agents to cause re-entrant VT.
• Option B: Option B is incorrect: quinidine's antimuscarinic properties tend to accelerate the sinus rate rather than suppress the sinus node; sinoatrial arrest is not quinidine's characteristic proarrhythmic risk.
• Option D: Option D is incorrect: quinidine's antimuscarinic properties actually enhance AV nodal conduction; complete AV block is not quinidine's primary proarrhythmic mechanism; the combination with AV nodal blockers can produce excessive rate slowing but is given to prevent flutter 1:1 conduction.
• Option E: Option E is incorrect: quinidine does not produce TdP or AF through alpha-adrenergic blocking effects on atrial tissue; triggered activity from EADs is the mechanism of quinidine-associated TdP in ventricular tissue, arising from IKr block. SECTION 3 — Integration & Advanced Reasoning (Questions 17–22)

ANSWER: A

Rationale:

The ECG patterns of the three Class I subclasses are mechanistically distinct and clinically measurable. Class Ia agents (quinidine, procainamide, disopyramide) produce two simultaneous ECG effects: moderate QRS widening from sodium channel blockade (intermediate recovery kinetics produce measurable but not excessive conduction slowing) and QTc prolongation from concurrent IKr blockade (which extends action potential duration and the repolarization phase). Patient 1's pattern of moderate QRS widening combined with QTc prolongation precisely matches this dual-effect signature. Class Ic agents (flecainide, propafenone) produce marked QRS widening from their slow-recovery sodium channel blockade (the most pronounced conduction slowing of all Class I subgroups) with minimal to no QTc prolongation because these agents have negligible IKr blocking activity. Patient 2's pattern of marked QRS widening without QTc change matches this profile. Class Ib agents (lidocaine, mexiletine) have fast-recovery kinetics that produce minimal net channel block at resting rates, minimal QRS widening, and no QTc prolongation (they actually shorten APD). Patient 3's minimal QRS change without QTc change is consistent with Class Ib.

• Option B: Option B is incorrect: it misassigns Patient 1 to Class Ic (which does not prolong QTc) and Patient 2 to Class Ia (which does not produce the most marked QRS widening); the QTc prolongation in Patient 1 specifically identifies a Class Ia agent.
• Option C: Option C is incorrect: Class Ib agents (mexiletine, lidocaine) do not have IKr-blocking properties and do not prolong QTc; the subclass assignments in this option are pharmacologically inaccurate.
• Option D: Option D is incorrect: Class Ic agents do not produce QTc prolongation through toxic sodium channel accumulation at any dose; the absence of IKr blockade is an intrinsic pharmacological property of this subclass, not a dose-dependent phenomenon.
• Option E: Option E is incorrect: the ECG distinctions between Class I subclasses are well-established and clinically measurable at therapeutic doses; dismissing them as non-manifesting in clinical practice contradicts both pharmacological principles and clinical observation.

ANSWER: E

Rationale:

Lidocaine systemic toxicity follows a predictable, concentration-dependent hierarchy that is clinically important because it provides an early warning system. Neural tissue has greater sensitivity to sodium channel blockade than cardiac tissue at equivalent plasma concentrations, producing the observed sequence. At plasma concentrations of approximately 3 to 6 mcg/mL, patients experience circumoral and perioral numbness, tinnitus, lightheadedness, and slurred speech ; the early CNS symptoms seen in this patient. At concentrations of approximately 5 to 9 mcg/mL, muscle twitching and seizures occur. Cardiac toxicity ; manifesting as QRS widening, PR prolongation, AV block, and potentially ventricular arrhythmias ; requires concentrations of approximately 8 to 12 mcg/mL, roughly two to four times the concentration producing initial CNS effects. This concentration gap between CNS and cardiac toxicity thresholds means that early CNS symptoms serve as a warning signal: a patient reporting circumoral numbness or tinnitus during lidocaine administration should prompt immediate dose reduction or cessation before cardiac toxicity supervenes. In this patient, the normal QRS and stable hemodynamics confirm that cardiac sodium channels (Nav1.5) have not yet been significantly blocked, consistent with plasma concentrations in the CNS toxicity zone but below the cardiac threshold.

• Option A: Option A is incorrect: the blood-brain barrier does not delay lidocaine CNS penetration; lidocaine is highly lipophilic and crosses the blood-brain barrier rapidly; CNS symptoms appear first because neural tissue has greater sensitivity, not because of delayed brain penetration.
• Option B: Option B is incorrect: lidocaine's CNS effects are mediated through sodium channel blockade in neuronal tissue, not through beta-adrenergic agonism or catecholamine release from the adrenal gland; lidocaine is not a sympathomimetic agent.
• Option C: Option C is incorrect: the CNS symptoms here represent genuine lidocaine systemic toxicity; QRS widening does not precede neurological symptoms; the observed sequence (CNS before cardiac) is correct, not a placebo effect.
• Option D: Option D is incorrect: while lidocaine does have differential affinity for different sodium channel isoforms, the primary explanation for the toxicity hierarchy is differential tissue sensitivity at equivalent plasma concentrations rather than absolute subtype selectivity; both CNS and cardiac toxicity involve sodium channel blockade.

ANSWER: B

Rationale:

Procainamide is metabolized by hepatic N-acetyltransferase 2 (NAT2) to its primary metabolite, N-acetylprocainamide (NAPA). Unlike procainamide, which has Class Ia pharmacological properties (sodium channel block plus IKr block), NAPA has predominantly Class III activity ; it blocks IKr potassium channels and prolongs action potential duration and the QT interval without significant sodium channel blocking activity. NAPA is eliminated almost entirely by renal excretion. In patients with renal impairment, NAPA clearance is reduced proportionally to CrCl, causing accumulation. When NAPA accumulates to toxic concentrations, its IKr blocking effect produces significant QTc prolongation and can cause torsades de pointes ; even when plasma procainamide concentrations are within the therapeutic range. This is the key clinical insight: monitoring only procainamide levels is insufficient in renal impairment; NAPA levels must also be measured. In patients with CrCl below 30 to 40 mL/min, procainamide is generally avoided or requires substantial dose reduction with careful NAPA monitoring, because the risk of NAPA-mediated TdP is substantial.

• Option A: Option A is incorrect: the question states that procainamide levels are within the therapeutic range; the complication is from NAPA accumulation rather than procainamide accumulation; sodium channel toxicity from procainamide would manifest as QRS widening and conduction abnormalities, not primarily as QTc prolongation and polymorphic VT.
• Option C: Option C is incorrect: procainamide does not undergo spontaneous hydrolysis to PABA in uremic plasma; its metabolic pathway is enzymatic acetylation by NAT2; PABA is a metabolite of the sulfonamide hydrolysis pathway unrelated to procainamide pharmacokinetics.
• Option D: Option D is incorrect: procainamide does not have clinically significant antimuscarinic properties affecting ventricular M2 receptors; anticholinergic ventricular effects are not the mechanism of QTc prolongation; M2 receptor density in the ventricle is minimal and not altered by renal failure in this manner.
• Option E: Option E is incorrect: DILS requires weeks to months of procainamide therapy to develop; a 48-hour course cannot produce DILS; the ANA-mediated myocardial deposition mechanism described is not the established pathophysiology of either DILS or procainamide-associated QTc prolongation.

ANSWER: D

Rationale:

This question integrates the two most distinctive pharmacological properties of disopyramide ; its negative inotropy and its antimuscarinic effect ; in the specific clinical context of HOCM with AF. Disopyramide's negative inotropic effect reduces myocardial contractility, which directly decreases the dynamic LVOT gradient in HOCM. The LVOT obstruction in HOCM is driven by hypercontractile systolic function combined with the Venturi-mediated systolic anterior motion of the mitral valve against the hypertrophied septum; reducing contractility diminishes the gradient and alleviates symptoms. This is a guideline-recognized niche indication for disopyramide where the negative inotropy that is otherwise an adverse effect becomes the mechanism of therapeutic benefit. However, disopyramide's antimuscarinic properties remove vagal tone from the AV node. In the context of AF, this enhancement of AV nodal conduction would increase the ventricular rate ; precisely the opposite of what is desired. Metoprolol (a beta-blocker) is therefore essential as a co-medication: it blocks sympathetic drive at the AV node, counteracts the vagolytic AV nodal enhancement from disopyramide, and provides effective ventricular rate control in AF. The combination thus achieves two simultaneous therapeutic goals: gradient reduction (disopyramide's negative inotropy) and rate control (metoprolol's AV nodal slowing).

• Option A: Option A is incorrect: disopyramide does not provide AV nodal rate control through IKr blockade; IKr blockade prolongs the action potential in ventricular myocardium, not AV nodal refractoriness in a rate-limiting manner; the mechanism described is pharmacologically inaccurate.
• Option B: Option B is incorrect: disopyramide does not have negative chronotropic effects on the AV node; its antimuscarinic properties actually enhance AV nodal conduction, which would worsen rate control if given without an AV nodal blocking agent.
• Option C: Option C is incorrect: disopyramide reduces the LVOT gradient through negative inotropy, not through vasodilation from alpha-adrenergic blocking properties; this mechanism describes quinidine or other agents with alpha-blocking activity; disopyramide's primary mechanism in HOCM is direct contractility reduction.
• Option E: Option E is incorrect: disopyramide and metoprolol are not independent agents working through additive rhythm control mechanisms; they are specifically paired because disopyramide's antimuscarinic effect requires counteraction by an AV nodal blocking agent; describing them as entirely independent misses the pharmacological interaction that makes the combination both necessary and rational.

ANSWER: C

Rationale:

This question tests nuanced application of the Class Ic contraindication in a patient with mild LVH ; a gray zone that requires clinical judgment rather than a binary rule. The CAST trial established the contraindication in post-MI structural heart disease, and subsequent guidelines extended this to HFrEF and significant structural heart disease. Mild to moderate LVH with preserved ejection fraction occupies an intermediate position: severe LVH (wall thickness above 14 to 16 mm), particularly with diastolic dysfunction or any systolic impairment, is generally considered a contraindication to Class Ic agents because the hypertrophied and remodeled myocardium creates heterogeneous conduction that increases proarrhythmic risk. Mild LVH (wall thickness 13 mm) with preserved EF and no coronary artery disease, as in this patient, does not invoke the same degree of structural concern and is generally considered acceptable by many clinicians for Class Ic use, though individualized assessment is required. Both flecainide and propafenone remain options. This question illustrates that the Class Ic "contraindication" is not a simple binary threshold but a spectrum of risk based on the degree and type of structural abnormality.

• Option A: Option A is incorrect: mild LVH with preserved EF is not an absolute contraindication to Class Ic agents in current clinical practice; the categorical claim that any LVH prohibits Class Ic use is overly broad and does not reflect guideline-based individualized decision-making.
• Option B: Option B is incorrect: propafenone's beta-blocking properties do not specifically protect against LVH-related proarrhythmia in a way that justifies using it but not flecainide; both agents carry similar Class Ic risk profiles in this patient; the mechanistic reasoning offered is pharmacologically unsupported.
• Option D: Option D is incorrect: the claim that propafenone is contraindicated because its beta-blocking properties cause reverse use-dependent sodium channel accumulation is pharmacologically incorrect; beta-blockade slows heart rate, which reduces (not increases) use-dependent sodium channel accumulation (since use-dependence increases with faster rates); the option also incorrectly applies the term reverse use-dependence to Class I kinetics, which is a concept specific to Class III agents.
• Option E: Option E is incorrect: while CAST specifically enrolled post-MI patients, the pharmacological principle of Class Ic proarrhythmia extends to other structural substrates including hypertensive LVH; dismissing the CAST principle as entirely irrelevant to LVH is not pharmacologically defensible.

ANSWER: A

Rationale:

This integration question tests knowledge of when each Class I subclass and agent is appropriate. Patient 1 (post-MI VT, structural heart disease, acute IV need): Class Ic agents are contraindicated by prior MI and HFrEF; Class Ia agents (procainamide) are an option for acute VT in structural disease and can be appropriate IV, though amiodarone is often preferred in modern practice; Class Ib lidocaine is appropriate for acute IV VT suppression and is specifically used in structural heart disease without the CAST contraindication ; it was the pre-amiodarone standard for VT in the cardiac care unit. Patient 2 (LQT3 + beta-blocker): mexiletine added to beta-blocker is the mechanistically targeted approach ; it specifically blocks INa,late from the gain-of-function SCN5A mutation responsible for LQT3, shortening the QTc. Patient 3 (HOCM + AF): disopyramide's negative inotropy reduces the LVOT gradient; mandatory co-prescription with a beta-blocker (or rate-limiting calcium channel blocker) is required to prevent the antimuscarinic AV nodal acceleration that would worsen rate control in AF. Patient 4 (AF, structurally normal): flecainide or propafenone with an AV nodal blocking agent is guideline-supported rhythm control; the AV nodal blocker is mandatory to prevent flutter 1:1 conduction. Patient 5: Option A honestly acknowledges that mexiletine is the oral Class Ib agent, but there is no IV Class Ib option beyond lidocaine itself for acute use, and adding another sodium channel blocker to a patient with suspected lidocaine toxicity requires careful reassessment.

• Option B: Option B is incorrect on multiple counts: flecainide IV is contraindicated in structural heart disease; quinidine does not counteract LQT3 and would worsen QTc prolongation; flecainide does not have meaningful negative inotropy for HOCM.
• Option C: Option C is incorrect: procainamide IV can be used for acute VT in structural heart disease, but the suggestion that NAPA's Class III activity is a therapeutic advantage (rather than an accumulation risk) misrepresents the pharmacology; quinidine worsens QTc in LQT3; flecainide with diltiazem is not the approach for HOCM.
• Option D: Option D is incorrect: mexiletine oral is not rapid enough for acute VT management; flecainide worsens LQT3 by reducing peak INa without addressing INa,late; lidocaine IV is not used for AF rhythm control.
• Option E: Option E is incorrect: while comprehensive evaluation is always appropriate, the matching exercise in this question reflects well-established Class I pharmacology principles that apply to the described patient profiles without requiring additional testing. REFERENCES 1. Catterall WA. Sodium channels and their pharmacology. Annu Rev Pharmacol Toxicol. 1980;20:15-43. 2. Harrison DC. Antiarrhythmic drug classification: new science and practical applications. Am J Cardiol. 1985;56(3):185-187. 3. Roden DM, Woosley RL. Flecainide. N Engl J Med. 1986;315(1):36-41. 4. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-788. 5. Josephson ME, Caracta AR, Ricciutti MA, Lau SH, Damato AN. Electrophysiologic properties of procainamide in man. Am J Cardiol. 1974;33(5):596-603. 6. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-1022. 7. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103(1):89-95. 8. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295-303. 9. Woosley RL. Antiarrhythmic drugs. Annu Rev Pharmacol Toxicol. 1991;31:427-455. 10. Rials SJ, Wu Y, Ford N, et al. Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart. Circulation. 1995;91(2):426-430. 11. Podrid PJ. Proarrhythmia: a serious complication of antiarrhythmic drugs. Curr Cardiol Rep. 1999;1(4):289-296. 12. Hohnloser SH, Zabel M. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol. 1992;70(5):3A-10A.